At the end of 2015, a news item pushed Samsung to the market in a different way: Samsung announced at the event held in Incheon, South Korea on December 21, local time that it is transferring business technology for chip and smartphone production to A new business, biomedical production . It plans to invest approximately RMB 4.7 billion to build the world's largest biopharmaceutical manufacturing plant in Songdo, Incheon. Does this mean that Samsung is going to make a big push into biopharmaceuticals? It may be too early, but this transformation is really surprising. Late biopharmaceutical As we all know, in recent years, Samsung has suffered setbacks in the mobile phone market, and its market share has been threatened and squeezed. The semiconductor industry, which has always been proud of it, has also been squeezed by Qualcomm and MediaTek, and wants to use the chip business. It will take some time to save the overall situation. On the other hand, the global biopharmaceutical industry is booming. According to data released by London-based research firm Evaluate, global biopharmaceutical production demand will triple by 2020, and the biotechnology market will exceed $278 billion in the next five years, compared with $184 billion this year. Some analysts believe that biopharmaceuticals as the new technology field will be the next ticket for Samsung's renaissance in this century . Of course, Samsung knows this. In the past four years, it has invested nearly $2.74 billion in large warehouse-scale production plants and R&D laboratories. Now, it is using the power of manufacturing chips and smart phones in the past to make biopharmaceuticals for the most well-known companies in the global pharmaceutical industry. Its goal is to become the world's largest contract manufacturer of biopharmaceuticals. For Samsung’s new head, Li Zaiyu, it is a test to vigorously promote investment in the biotechnology field. He believes that biotechnology is a fast-growing area that can help boost the group's profit growth. Earlier this year, Lee attended the forum in China and said, "We have seen opportunities to integrate information technology, drugs and biologics." As the de facto controller of Samsung's "business empire", Li Zaiyu has an international vision, emphasizes technological innovation and globalization strategy, and pays attention to the relationship with important partners such as Lenovo. He hopes to transform Samsung from the world's largest technology company to The most innovative technology company in the world. In order to help Samsung to maintain a firm foothold in biopharmaceuticals, Li made a big investment. In four years, the group spent $1 billion to create two factories that produce biopharmaceuticals for pharmaceutical companies, and spent $1 billion to build their own biotech R&D projects. According to the data, Samsung Biopharmaceuticals was founded in 2011 and 97% is controlled by Samsung Electronics. In late November, Samsung Biologics said that the company will spend $740 million to build a new plant in South Korea, and the capacity of the pharmaceutical plant will double after completion. When the new plant is completed in 2018, combined with the existing and under construction two, Samsung is expected to become the world's largest pharmaceutical manufacturer. However, things may not develop as smoothly as they expected. For Samsung, the pharmaceutical process is far more complex and demanding than the process of manufacturing semiconductors. Be aware that a grain of dust can interrupt production. In addition, Samsung's expansion in the field of biosimilars is still facing the unfavorable situation of competition between large pharmaceutical companies such as Pfizer and Anjin, and the market is still immature; although countries such as Europe and Japan allow generic drugs to be sold, the United States has not yet issued specific regulations. And did not approve any such generic biopharmaceutical sales. Therefore, in addition to biopharmaceuticals, Li Zaiyu is still actively using the contacts in his global elite circle to find new areas for cooperation & investment, and this new field is the digital health industry. In fact, when Li took over the Samsung Empire, he was considering the way out of Samsung's new era, and he had a lot of ambitions in the field of mobile medicine , and this should start from the rise of the Samsung Empire and his life. Magnesium Fortifier,Magnesium Sulfate Dried Product,Magnesium Sulfate Heptahydrate,Anhydrous Magnesium Sulfate LIANYUNGANGLONGTAIWEI FOOD INGREDIENTS CO.,LTD. , https://www.longtaiweifood.com
